Early febrile events in 62 patients with relapsed/refractory B-cell NHL treated with CD19-CAR-T were characterized as infections or cytokine release syndrome (CRS), and PCT was particularly high in infected patients compared with CRS (optimal threshold for discrimination was 1.5 μg/L) (Rejeski et al., 2023). The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.